Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice - PubMed (original) (raw)

. 2006 Jun;1762(6):616-26.

doi: 10.1016/j.bbadis.2006.03.004. Epub 2006 Apr 17.

Affiliations

• PMID: 16647250
• DOI: 10.1016/j.bbadis.2006.03.004

Free article

Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice

Karen M Smith et al. Biochim Biophys Acta. 2006 Jun.

Free article

Abstract

There is substantial evidence that a bioenergetic defect may play a role in the pathogenesis of Huntington's Disease (HD). A potential therapy for remediating defective energy metabolism is the mitochondrial cofactor, coenzyme Q10 (CoQ10). We have reported that CoQ10 is neuroprotective in the R6/2 transgenic mouse model of HD. Based upon the encouraging results of the CARE-HD trial and recent evidence that high-dose CoQ10 slows the progressive functional decline in Parkinson's disease, we performed a dose ranging study administering high levels of CoQ10 from two commercial sources in R6/2 mice to determine enhanced efficacy. High dose CoQ10 significantly extended survival in R6/2 mice, the degree of which was dose- and source-dependent. CoQ10 resulted in a marked improvement in motor performance and grip strength, with a reduction in weight loss, brain atrophy, and huntingtin inclusions in treated R6/2 mice. Brain levels of CoQ10 and CoQ9 were significantly lower in R6/2 mice, in comparison to wild type littermate control mice. Oral administration of CoQ10 elevated CoQ10 plasma levels and significantly increased brain levels of CoQ9, CoQ10, and ATP in R6/2 mice, while reducing 8-hydroxy-2-deoxyguanosine concentrations, a marker of oxidative damage. We demonstrate that high-dose administration of CoQ10 exerts a greater therapeutic benefit in a dose dependent manner in R6/2 mice than previously reported and suggest that clinical trials using high dose CoQ10 in HD patients are warranted.

PubMed Disclaimer

Similar articles

• Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice.
  Stack EC, Smith KM, Ryu H, Cormier K, Chen M, Hagerty SW, Del Signore SJ, Cudkowicz ME, Friedlander RM, Ferrante RJ. Stack EC, et al. Biochim Biophys Acta. 2006 Mar;1762(3):373-80. doi: 10.1016/j.bbadis.2005.11.002. Epub 2005 Dec 5. Biochim Biophys Acta. 2006. PMID: 16364609
• Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.
  Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF. Ferrante RJ, et al. J Neurosci. 2002 Mar 1;22(5):1592-9. doi: 10.1523/JNEUROSCI.22-05-01592.2002. J Neurosci. 2002. PMID: 11880489 Free PMC article.
• Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice.
  Schilling G, Savonenko AV, Coonfield ML, Morton JL, Vorovich E, Gale A, Neslon C, Chan N, Eaton M, Fromholt D, Ross CA, Borchelt DR. Schilling G, et al. Exp Neurol. 2004 May;187(1):137-49. doi: 10.1016/j.expneurol.2004.01.003. Exp Neurol. 2004. PMID: 15081595
• Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases.
  Beal MF. Beal MF. Biofactors. 1999;9(2-4):261-6. doi: 10.1002/biof.5520090222. Biofactors. 1999. PMID: 10416039 Review.
• Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations.
  Bhagavan HN, Chopra RK. Bhagavan HN, et al. Mitochondrion. 2007 Jun;7 Suppl:S78-88. doi: 10.1016/j.mito.2007.03.003. Epub 2007 Mar 27. Mitochondrion. 2007. PMID: 17482886 Review.

Cited by

• Coenzyme Q10 Supplementation Increases Removal of the ATXN3 Polyglutamine Repeat, Reducing Cerebellar Degeneration and Improving Motor Dysfunction in Murine Spinocerebellar Ataxia Type 3.
  Wu YL, Chang JC, Sun HL, Cheng WL, Yen YP, Lin YS, Chao YC, Liu KH, Huang CS, Liu KL, Liu CS. Wu YL, et al. Nutrients. 2022 Aug 31;14(17):3593. doi: 10.3390/nu14173593. Nutrients. 2022. PMID: 36079853 Free PMC article.
• Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.
  Switonski PM, Szlachcic WJ, Gabka A, Krzyzosiak WJ, Figiel M. Switonski PM, et al. Mol Neurobiol. 2012 Oct;46(2):430-66. doi: 10.1007/s12035-012-8316-3. Epub 2012 Sep 4. Mol Neurobiol. 2012. PMID: 22944909 Free PMC article. Review.
• Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline.
  Menalled LB, Patry M, Ragland N, Lowden PA, Goodman J, Minnich J, Zahasky B, Park L, Leeds J, Howland D, Signer E, Tobin AJ, Brunner D. Menalled LB, et al. PLoS One. 2010 Mar 22;5(3):e9793. doi: 10.1371/journal.pone.0009793. PLoS One. 2010. PMID: 20339553 Free PMC article.
• CoQ10 Deficient Endothelial Cell Culture Model for the Investigation of CoQ10 Blood-Brain Barrier Transport.
  Wainwright L, Hargreaves IP, Georgian AR, Turner C, Dalton RN, Abbott NJ, Heales SJR, Preston JE. Wainwright L, et al. J Clin Med. 2020 Oct 10;9(10):3236. doi: 10.3390/jcm9103236. J Clin Med. 2020. PMID: 33050406 Free PMC article.
• Involvement of Coenzyme Q10 in Various Neurodegenerative and Psychiatric Diseases.
  Ebrahimi A, Kamyab A, Hosseini S, Ebrahimi S, Ashkani-Esfahani S. Ebrahimi A, et al. Biochem Res Int. 2023 Nov 1;2023:5510874. doi: 10.1155/2023/5510874. eCollection 2023. Biochem Res Int. 2023. PMID: 37946741 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Medical

  • MedlinePlus Health Information